Ocata Therapeutics Inc fka OCAT

[crawford2012]

For those of you who ask and would like some answers...here is something that will provide some sort of answer that I hope makes you feel good.
I have shared my thoughts before about when we should expect a movement in our stock and just would like to share with those of you that are stressing out due to the drop in price of the share price.

I am going to give it to you from the horse’s mouth..(Gary Rabin)...
First, we are not going to the moon yet...we are still in the I/II clinical trials...and we have more patients to enroll.
This is why we are in pause mode now.
Second, we are not going to see a day below $0.10. The chance of this has passed...as we get closer to an update, no one is going to sell their shares cheap...in the next few weeks (starting this coming monday), we should start to see a movement upward and a sudden pop with "good news" I hope.

Again, thank you all for allowing me to share my thoughts with you out loud. I hope you can sense the seriousness that ACT is treating those clinical trials with and I am glad they are. Enjoy reading the part that I have extracted below from the full article.


I know that many investors want us to go as fast as possible in treating patients. But there is a tortoise/hare effect here that I simply won’t discuss now. I know that it is hard to be patient, but we are making every decision for the best interest of the company in the long run. We don’t get bonus points for finishing the trial a few months earlier as compared to making it a truly game-changing medical opportunity. I know that many of you don’t know me from Adam, but I’m a very methodical person. Look who we recently added to the Board – one of the leading scientists in the world; one of the best entrepreneurs in the world (founder of Life Alert and eFax), and the CFO of a highly-regarded biotech company considered to have made excellent, value-preserving large bio/pharma partnering deals. We have this under control.

One ill-conceived decision could set the company on a downward path (ACT has been there). Highly prestigious peer-reviewed medical journals do substantial review and due diligence. Top-rated eye hospitals and surgeons are very process-oriented and sometimes bureaucratic. Pushing them harder to move faster doesn’t earn you any credibility or success.


source:http://advancedcell.com/news-and-media/press-releases/advanced-cell-technology-to-present-at-2011-stem-cell-meeting-on-the-mesa-s-investor-and-partnering-forum/index.asp